Substituted quinazolinones for inhibiting PI3K

The present invention relates to novel quinazolinone derivatives inhibiting PI3K; a method for preparing the derivatives; and a pharmaceutical composition for treating hematologic neoplasms or liver diseases, containing the quinazolinone derivatives, wherein the novel quinazolinone derivatives accor...

Full description

Saved in:
Bibliographic Details
Main Authors Kim, Jongwoo, Lee, Chiwoo, Hong, Suji
Format Patent
LanguageEnglish
Published 03.03.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to novel quinazolinone derivatives inhibiting PI3K; a method for preparing the derivatives; and a pharmaceutical composition for treating hematologic neoplasms or liver diseases, containing the quinazolinone derivatives, wherein the novel quinazolinone derivatives according to the present invention have a beneficial effect in the treatment of hematologic neoplasms or liver diseases. Particularly, the quinazolinone derivatives inhibit PI3K´ with high selectivity compared to that of a conventional anticancer drug of PI3K´ inhibitors, thereby significantly reducing immunotoxicity, or simultaneously inhibit PI3K´ and PI3K³, thereby enabling the treatment of autoimmune diseases, and anticancer therapy for blood cancer and the like. These targeted drugs have an advantage of enabling the problem of side effects of a conventional highly toxic anticancer therapy to be resolved.
Bibliography:Application Number: US201916244368